Cramer's Investing Club Profile: Eli Lilly has one of best pipelines in the drug industry

January 31, 2022
Unlike many of its peers, Eli Lilly's growth story is durable and volume-driven due to the strength of its recent drug launches.

from Health and Science https://ift.tt/zypuwNEKP
https://ift.tt/KMwdm4615
https://ift.tt/jO5JYud8a

Leave a Comment

No comments

Subscribe to: Post Comments ( Atom )
Powered by Blogger.